The Effect of Glucomannan Powder on Improving Gut Microbiota.

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07231003

Enrollment

Registered

2025-11-17

Start date

2025-08-28

Completion date

2026-12-31

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysbiosis

Keywords

dysbiosis, Glucomannan, gut-microbiota

Brief summary

The object of this study is evaluating the effects of the Glucommanan on the healthy human subjects who are. In this trial, at most 30 healthy subjects whose ages are 20\ 65 years old (15 for placebo and 15 for intervention)will be included. The total experiment will be 9 weeks and the intervention period will be 6 weeks, within which, at week 0, 6, and 7, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST, also known as GOT), alanine aminotransferase (ALT, also known as GPT), blood urea nitrogen (BUN), serum creatinine (Cr), fasting blood glucose (Glucose, AC) and adiponectin would be measured. Feces samples and anthropometric data will also be acquired. The results will be analyzed according to the methods published by the Ministry of Health and Welfare of Taiwan Food and Drug Administration.

Interventions

DIETARY_SUPPLEMENTGlucomannan

2 packs of glucomannan, 2 grams per pack

DIETARY_SUPPLEMENTPlacebo

2 packs of corn starch, 2 grams per pack

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

\- Both genders, aged between 20 and 65 years. No history of gastrointestinal disorders or other significant health issues. Overall good health.

Exclusion criteria

\- Participants who have taken antibiotics or any medications/supplements that could affect the gut microbiota within 1 week prior to the experiment or during the study. Pregnant or breastfeeding women. Smokers or individuals with excessive alcohol consumption. Chronic disease medication usage for less than 3 months. Postmenopausal women on hormone replacement therapy. Individuals with acute illnesses such as a cold.

Design outcomes

Primary

Measure	Time frame	Description
gut microbiota	Week(0) (Baseline), Wk(6),Wk7	Evaluation of Gut Microbiota by Analysis of Four Indicator Strains and 16S rRNA Sequencing Using Fecal Samples

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026